Search Results

Reduced lipoprotein (a) in patients with severe hypertriglyceridaemia.

• Authors : Jacob EO; Department of Biochemistry, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.; Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

Subjects: Hypertriglyceridemia*/Hypertriglyceridemia*/Hypertriglyceridemia*/blood ; Lipoprotein(a)*/Lipoprotein(a)*/Lipoprotein(a)*/blood ; Triglycerides*/Triglycerides*/Triglycerides*/blood

• Source: The Journal of international medical research [J Int Med Res] 2024 Oct; Vol. 52 (10), pp. 3000605241289294.Publisher: Sage Publications Country of Publication: England NLM ID: 0346411 Publication Model: Print Cited Medium: Internet ISSN: 1473-2300

Record details

The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study.

• Authors : Li Z; Cardiometabolic Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100037, China.; Gao Y

Subjects: Triglycerides*/Triglycerides*/Triglycerides*/blood ; Cholesterol, LDL*/Cholesterol, LDL*/Cholesterol, LDL*/blood ; Lipoprotein(a)*/Lipoprotein(a)*/Lipoprotein(a)*/blood

• Source: Lipids in health and disease [Lipids Health Dis] 2024 May 07; Vol. 23 (1), pp. 134. Date of Electronic Publication: 2024 May 07.Publisher: BioMed Central Country of Publication: England NLM ID: 101147696 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-511X

Record details

Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.

• Authors : Hoogeveen RC; Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX.; Ballantyne CM

Subjects: Atherosclerosis/Atherosclerosis/Atherosclerosis/*prevention & control ; Cholesterol, LDL/Cholesterol, LDL/Cholesterol, LDL/*metabolism ; Hypolipidemic Agents/Hypolipidemic Agents/Hypolipidemic Agents/*therapeutic use

• Source: Clinical chemistry [Clin Chem] 2021 Jan 08; Vol. 67 (1), pp. 143-153.Publisher: Oxford University Press Country of Publication: England NLM ID: 9421549 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.

• Authors : Hamamura H; Department of Internal Medicine, Division of Cardio-Vascular Medicine, Kurume University School of Medicine.; Adachi H

Subjects: Insulin Resistance*; Cholesterol, LDL/Cholesterol, LDL/Cholesterol, LDL/*blood ; Lipoprotein(a)/Lipoprotein(a)/Lipoprotein(a)/*blood

• Source: Journal of atherosclerosis and thrombosis [J Atheroscler Thromb] 2021 Apr 01; Vol. 28 (4), pp. 329-337. Date of Electronic Publication: 2020 Jul 04.Publisher: Japan Atherosclerosis Society Country of Publication: Japan NLM ID: 9506298 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Agricola

Record details

Association of lipid profile with decompensation, liver dysfunction, and mortality in patients with liver cirrhosis.

• Authors : Feng R; Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), Shenyang, Liaoning, P.R. China.; Postgraduate College, Jinzhou Medical University, Jinzhou, Liaoning P R. China.

Subjects: Liver Cirrhosis*/Liver Cirrhosis*/Liver Cirrhosis*/complications ; Liver Cirrhosis*/Liver Cirrhosis*/Liver Cirrhosis*/diagnosis ; Liver Cirrhosis*/Liver Cirrhosis*/Liver Cirrhosis*/metabolism

• Source: Postgraduate medicine [Postgrad Med] 2021 Aug; Vol. 133 (6), pp. 626-638. Date of Electronic Publication: 2021 Jun 16.Publisher: Informa Healthcare Country of Publication: England NLM ID: 0401147 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Current Role of Lipoprotein Apheresis.

• Authors : Thompson G; Department of Metabolic Medicine, Imperial College London, Hammersmith Hospital, Ducane Road, London, W12 0NN, UK. .; Parhofer KG

Subjects: Blood Component Removal/Blood Component Removal/Blood Component Removal/*methods ; Cholesterol, LDL/Cholesterol, LDL/Cholesterol, LDL/*blood ; Hypercholesterolemia/Hypercholesterolemia/Hypercholesterolemia/*therapy

• Source: Current atherosclerosis reports [Curr Atheroscler Rep] 2019 May 01; Vol. 21 (7), pp. 26. Date of Electronic Publication: 2019 May 01.Publisher: Springer Country of Publication: United States NLM ID: 100897685 Publication Model: Electronic Cited Medium: Internet ISSN: 1534-6242

Record details

Changes in the ratio between apolipoprotein (a) and lipids in human plasma during interaction with polyclonal sheep antibodies against lipoprotein (a).

• Authors : Chernyad'eva IF; Laboratory of Hemodialysis and Plasmapheresis, A. L. Myasnikov Institute of Cardiology, Russian Research-and-Production Center for Cardiology, Russian Ministry of Health, Moscow.; Lopata NS

Subjects: Antibodies/Antibodies/Antibodies/*immunology ; Apolipoproteins/Apolipoproteins/Apolipoproteins/*blood ; Cholesterol/Cholesterol/Cholesterol/*blood

• Source: Bulletin of experimental biology and medicine [Bull Exp Biol Med] 2002 Apr; Vol. 133 (4), pp. 354-6.Publisher: Springer Country of Publication: United States NLM ID: 0372557 Publication Model: Print Cited Medium: Print ISSN: 0007-4888 (Print)

Record details

Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

• Authors : Albers JJ; Northwest Lipid Metabolism and Diabetes Research Laboratories, Department of Medicine, University of Washington, Seattle, Washington.; Slee A

Subjects: Apolipoprotein A-I/Apolipoprotein A-I/Apolipoprotein A-I/*blood ; Apolipoproteins B/Apolipoproteins B/Apolipoproteins B/*blood ; Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*blood

• Source: Journal of the American College of Cardiology [J Am Coll Cardiol] 2013 Oct 22; Vol. 62 (17), pp. 1575-9. Date of Electronic Publication: 2013 Aug 21.Publisher: Elsevier Biomedical Country of Publication: United States NLM ID: 8301365 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups.

• Authors : Konerman M; Department of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA. ; Kulkarni K

Subjects: Cholesterol, HDL/Cholesterol, HDL/Cholesterol, HDL/*blood ; Cholesterol, LDL/Cholesterol, LDL/Cholesterol, LDL/*blood ; Lipoprotein(a)/Lipoprotein(a)/Lipoprotein(a)/*blood

• Source: Journal of clinical lipidology [J Clin Lipidol] 2012 Jul-Aug; Vol. 6 (4), pp. 368-73. Date of Electronic Publication: 2012 Jan 21.Publisher: Elsevier Country of Publication: United States NLM ID: 101300157 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details